ZiaDerm Research is currently enrolling participants for a lichen planus clinical trial in the Miami, Aventura, Broward, and Fort Lauderdale areas. Qualified participants will receive all study-related care from an experienced clinical research team. The study is comparing upadacitinib with a standard corticosteroid treatment approach for adults with moderate-to-severe cutaneous lichen planus.
To Qualify:
- Must be 18 to 63 years of age
- Have lichen planus affecting the skin
- Have active moderate-to-severe lichen planus
- Have significant itching from lichen planus
- Be willing to travel to our locations and complete the required study visits
- No insurance is needed
- All study-related care is provided at no cost
- Participants may qualify for compensation for their time
The study requires participants to have biopsy-confirmed cutaneous lichen planus, moderate-to-severe disease defined by study assessments, and a baseline Worst Itch NRS score of at least 7 out of 10. A biopsy can be performed as part of study screening if needed.
To learn more, fill out the form on this page or call (786) 589-5183.
NO COST. NO INSURANCE. MAY QUALIFY FOR COMPENSATION.
Participants May Be Compensated for Their Time
- The study includes a 16-week treatment period
- Participants return for study visits at Screening, Baseline, and approximately Weeks 4, 8, 12, and 16
- A safety follow-up visit occurs approximately 30 days after treatment
- Participants are randomly assigned to one of two treatment groups
- One group receives upadacitinib once daily
- The other group receives a 12-day oral prednisone taper plus topical clobetasol through Week 16
The study includes up to a 14-day screening/washout period, 16 weeks of treatment, and a 30-day safety follow-up.
What Is Lichen Planus?
Lichen planus is an inflammatory condition that can affect the skin and may cause itchy, raised, discolored lesions. For some people, the condition can be widespread, persistent, and difficult to control.
This clinical trial is studying whether upadacitinib, a JAK1 inhibitor, can provide better itch relief and skin lesion improvement than a standard treatment approach using oral prednisone and topical corticosteroids. There are currently no FDA-approved treatments specifically for lichen planus, and available treatments are commonly used off-label.
Participants are randomly assigned 1:1 to one of two groups. One group receives upadacitinib 15 mg once daily for 16 weeks, with a protocol-defined possibility of increasing to 30 mg daily beginning after Week 4 if response and safety criteria are met. The other group receives a 12-day prednisone taper along with clobetasol 0.05% applied twice daily through Week 16.
We are seeking adults with active, moderate-to-severe lichen planus of the skin who are experiencing substantial itching. If this applies to you, you may qualify for the study.
About ZiaDerm Research
ZiaDerm Research is a clinical research center with more than 20 years of experience conducting dermatology clinical trials. Our experienced research staff and board-certified dermatologists have conducted hundreds of studies for companies including AbbVie, Eli Lilly, Galderma, and Pfizer.
ZiaDerm Research conducts Phase 2 through Phase 4 clinical trials, with participant safety as a top priority. To learn more about this lichen planus clinical trial, the time commitment, participant responsibilities, and what to expect, fill out the form or call (786) 589-5183.